Genrix Bio announced on the evening of February 26 that its Phase III clinical trial of "Telicibaimab Injection (GR1802 Injection)" for the indication of adult seasonal allergic rhinitis has met the primary endpoint. The company has submitted a new drug application for this indication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and it has been accepted (acceptance number: CXSS2600031).
According to available information, telithiasismab injection is a recombinant fully human anti-IL-4Rα monoclonal antibody independently developed by the company, targeting IL-4Rα. This drug specifically binds to human IL-4Rα on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4Rα, inhibiting downstream STAT6 phosphorylation, and suppressing CD23 upregulation, thereby inhibiting Th2-type inflammatory responses mediated by IL-4 or IL-13.

According to reports, the new drug application for telixirizabab injection for the treatment of moderate to severe atopic dermatitis in adults was accepted in September 2025. Several other indications are in the clinical trial stage, including chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and adolescent seasonal allergic rhinitis in Phase III clinical trials, asthma in Phase II clinical trials, and childhood/adolescent atopic dermatitis in Phase Ib/IIa clinical trials.

To date, only two drugs targeting the same target as telizumab injection (GR1802 injection) have been approved for marketing in China.

Genrix Bio also released its 2025 preliminary financial results. According to preliminary calculations, the company expects to achieve operating revenue of 231 million yuan last year, a significant increase of 666.65% year-on-year; net profit attributable to the parent company is -536 million yuan, a 32.74% reduction in losses compared to the same period last year. This is mainly due to the company's further efforts to expand the sales market of its first commercialized product, Celecium Absorb Injection (Jinlixi®), during the reporting period, resulting in steady year-on-year growth in product sales revenue; at the same time, the licensing revenue corresponding to the contractual obligations of the GR1803 injection licensing and commercialization agreement was substantial, which had a positive impact on the net profit for the period.

https://finance.eastmoney.com/a/202602263655577488.html